陳林正
管理合夥人


在2014年創立康禧之前,陳先生是Permira的全球合夥人和亞洲聯席主管。 Permira是一家擁有全球視野的歐洲私募基金,擁有約200億歐元的承諾資本。在Permira任職期間,陳先生進行了包括亞洲廣播衛星和銀河娛樂集團在內的多項投資交易。


在2008年加入Permira之前,陳先生在高盛投資銀行部從事了9年的投行工作,在此期間他任董事總經理並且是亞洲(除日本外)一般工業組的聯席主管,該組的業務涵蓋了消費零售、醫藥醫療、工業和交通等領域。在此之前,陳先生是紐約和香港的達維律師事務所(Davis Polk)的公司金融律師。



陳先生從哈佛大學獲得了學士和碩士學位,並從哈佛法學院獲得法學博士學位。

Henry Chen
Managing Partner


Prior to establishing Delos in 2014, Mr. Chen was a Partner and Co-Head of Asia at Permira, a European private equity firm with global reach and a total committed capital of approximately €20bn. While at Permira, Mr. Chen worked on a number of transactions including Asia Broadcast Satellite and Galaxy Entertainment Group.
Prior to joining Permira in 2008, Mr. Chen spent nine years in Investment Banking at Goldman Sachs, where he was a Managing Director and co-headed the General Industrials Group, Asia (excluding Japan) which covered consumer retail, healthcare, industrials and transportation sectors. Prior to that, Mr. Chen was a corporate finance lawyer with Davis Polk in New York and Hong Kong.
Mr. Chen holds Bachelor and Masters degrees from Harvard University, USA, and has a Juris Doctorate degree from Harvard Law School, USA.



Dr. Samuel Yin
Partner


Dr. Yin has been the President of Ruentex Group since 1994 and serves as its Chief Executive Officer. Ruentex Group invests in textile, retail, financial services and real estate, and is a major shareholder of Nan Shan Insurance and Sun Art Retail Group, which operates RTMart and Auchan hypermarkets in ChinaDr. Yin serves as a Director at APT Satellite Company Limited and APT Satellite Holdings Ltd. since January 2003. He serves as a Director at APT Satellite Investment Company Limited and Sinopac Holdings. 
Dr. Yin received a master’s degree in Business at the National Taiwan University in 1983 and a Ph.D in business at the National Chengchi University in 1988. In 2004, Yin was named fellow of the Chinese Institute of Civil and Hydraulic Engineering. In 2008, he was invited to join Russia's International Academy of Engineering and also awarded the Engineering Prowess Medal, the academy's highest honour. In 2010, Yin received the Henry L. Michel Award for Industry Advancement of Research by the prestigious American Society of Civil Engineers (ASCE) for his contribution in the area of construction technology research.
Dr. Yin established the Tang Prize in December 2012. The mission of the prize is to promote research that is beneficial to the world and humankind, promote Chinese culture and make the world a better place. The prize pays out the equivalent of 1.7 million USD in categories of sustainable development, biopharmaceutical science, sinology and the "rule of law”.
Yin also provides financial and leadership support for the following foundations in Taiwan and China: the Yin Xun-Ruo Educational Foundation, the Yin Shu-Tien Medical Foundation, the Kwang-Hua Education Foundation, and the Guanghua School of Management of Peking University.



Dr. Michael Chang
Partner


Dr. Chang is the Chairman of OBI,  and founder of both Optimer Pharmaceuticals and OBI. In 1994, Dr. Chang established Pharmanex, a health products company, which was acquired by NuSkin Enterprises, where he was appointed Chief Scientific Adviser. Prior to this, he founded Cinogen in 1993. Dr. Chang was formerly the Director of Medical Chemistry at Rhone-Poulenc Rorer and Deputy Director of Medicinal Chemistry at Merck, Sharpe & Dohme (US Merck). 

Dr. Chang received his Ph.D. in Organic Chemistry from Brandeis University, and conducted postdoctoral research at MIT. He received his BS in Chemistry from Fu Jen Catholic University in Taiwan. He holds 39 patents and has published more than 69 scientific papers in peer reviewed journals.


Frank Chen
Partner


Mr. Chi-Chuan Chen is a Vice President and Special Assistant to the Chief Executive Officer at Ruentex Group. He has served in the Investment Management Department at Ruentex Group since 1987.

Mr. Chen holds a B.S. in chemical engineering and an MBA from National Taiwan University.



Founding Partners                                  創始合夥人

張念慈博士
合夥人


張念慈博士是台灣浩鼎生技股份有限公司(OBI)的董事長,也是Optimer制藥公司和OBI的創始人。在1994年,張博士創立了保健品公司華茂集團(Pharmanex),後被如新集團(NuSkin Enterprises)收購並被該公司任命爲首席科學顧問。在此之前他在1993年成立了Cinogen。張博士之前是羅納·普朗克·樂安公司(Rhone-Poulenc Rorer)醫學化學部的總監和默沙東(美國默沙東)醫學化學部的副總監。

張博士從布蘭迪斯大學獲得了有機化學的博士學位,並在麻省理工大學從事博士後研究。他從台灣的輔仁大學獲得了化學理學學士學位。他持有39份專利,並且在同行評審期刊上發表了超過60份科學論文。

陳志全
合夥人


​陳先生是潤泰集團投資管理處副總經理及總裁特別助理長。陳先生從1987年以來即任職于潤泰集團投資管理處。

陳先生從國立台灣大學獲得化學工程學士學位,以及商學研究所碩士學位。


尹衍樑博士
合夥人


尹衍樑博士自1994年以來擔任潤泰集團(Ruentex Group)的總裁且目前擔任該集團的首席執行官。潤泰集團在紡織、零售、金融服務以及地產等領域均有投資,並且是台灣南山人壽保險和高鑫零售的主要股東,高鑫零售在中國運營大潤發超市和歐尚超市。尹博士自2003年1月起擔任亞太通信衛星有限公司(APT Satellite Company Limited)和亞太衛星控股有限公司(APT Satellite Holdings Ltd.)的董事。自2002年3月1日起擔任宏基股份有限公司的董事。
尹博士在1983年從國立台灣大學獲得了MBA學位並在1987年從國立政治大學獲得了工商管理博士學位。尹博士於1983年從國立台灣大學獲得了MBA學位並在1988年從國立政治大學獲得了工商管理博士學位。在2004年尹先生被授予中國土木和水利學會的“會士”身份。在2008年,他受邀加入俄羅斯國際工程院並被授予工程實力獎章,該獎章代表了該學院的最高榮譽。在2010年尹博士因其在建築科技領域的貢獻而接受了享有盛譽的美國土木工程師學會(ASCE)頒發的產業研發成就獎(Henry L. Michel Award)。



尹博士於2012年12月設立了唐獎。該獎項旨在鼓勵推進對世界和人類有益的研究,宣傳中國文化,致力於造福世界。該獎項的獎金折合成美元約為170萬美元,涵蓋了可持續發展、生物製藥學、漢學和“法治”類別。


尹博士同時也為台灣和中國大陸的下列基金會提供經濟和管理支持:尹珣若教育基金會、尹書田醫學基金會、光華教育基金會和北大光華管理學院。